Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Scientists have found a way to prove that biochemical signals sent from cell to cell play an important role in determining how those cells develop.
A simple, marine-dwelling creature known as Trichoplax adhaerens has some remarkable properties. The organism can tolerate unusually high doses of radiation that would kill most other forms of life. T. adhaerens has another intriguing characteristic: the ability to resist cancer.
Every day, the billions of bacteria that inhabit your digestive system change; the food you eat, medications you take, and germs you're exposed to make some bacteria flourish more than others.
Scientists recently pinpointed the mechanism by which inhibitors of the ERK5 protein kinase diminish cancer cell proliferation and trigger their death.
We speak to Professor Charles Easley about his latest research into male infertility, and how sperm cells could be potentially developed from primate stem cells.
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy.
Tumors are heterogeneous, which means that different parts of the same tumor can be genetically distinct. This phenomenon, known as intratumor heterogeneity, is steadily gaining in significance within the field of cancer research.
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.
It sounds like the stuff of science fiction: a man-made crystal that can be attached to antibodies and then supercharge them with potent drugs or imaging agents that can seek out diseased cells with the highest precision, resulting in fewer adverse effects for the patient.
Immunotherapies are exhibiting better clinical benefit in the treatment of numerous cancers, particularly when used along with chemotherapy.
A type of cell transformation known as EMT enables cancer cells to break away from the tumor and form metastases elsewhere.
Even within a single patient with cancer, there is a vast diversity of individual tumor cells, which display distinct behaviors related to growth, metastasis, and responses to chemotherapy.
Researchers examined tumor cells that were resistant to the original treatment and identified molecular targets for therapies that could evade breast cancer recurrence.
Immunotherapy is a promising strategy to treat cancer by stimulating the body's own immune system to destroy tumor cells, but it only works for a handful of cancers. MIT researchers have now discovered a new way to jump-start the immune system to attack tumors, which they hope could allow immunotherapy to be used against more types of cancer.
Cancerous tumors are made up of many more components than just malignant cells from the tissue of origin. Immune cells can be recruited to the tumor site and form what is known as the tumor microenvironment.
More than 40,000 allogeneic hematopoietic stem cell transplants are carried out worldwide every year, mostly for patients suffering from leukemia or other diseases of the hematopoietic system.
Imagine you're about to go on a cross-country trip, stopping at spots along the way to admire local attractions.
Hepatitis C virus thrives in humans for years, damaging the liver by causing chronic inflammation, eventually resulting in cirrhosis and liver cancer.
AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.
Researchers generated a 3D pancreatic cancer tumor model in the lab, merging a bioengineered matrix and patient-derived cells.